Oncology highlights from AACR 2026

Oncology highlights from AACR 2026

From VJOncology Podcast by VJOncology

May 1, 2026 · 18 min · Episode 226

About this episode

The episode discusses key updates from the 2026 AACR meeting focusing on immuno-oncology and targeted therapy.

In this week’s VJOncology podcast, we bring you key updates from the 2026 AACR meeting across early-phase immuno-oncology and targeted therapy. Join leading experts Bruno Bockorny, Beth Israel Deaconess Medical Center, Boston, MA, Byoung Chul Cho, Yonsei University, Seoul, South Korea, Kristen Pauken, and Timothy Yap, MD Anderson Cancer Center, Houston, TX, as they discuss the clinical challenges of immune-related adverse events with checkpoint inhibitors, early signals from first-in-human studies of PLN-101095 in refractory solid tumors, emerging safety and activity data from a Phase I dose-escalation study of denikitug, and updated results of elisrasib monotherapy in previously treated KRAS G12C-mutant non-small cell lung cancer.

People in this episode

Guests: Bruno Bockorny, Byoung Chul Cho, Kristen Pauken, Timothy Yap

Topics covered

  • immuno-oncology
  • targeted therapy
  • clinical challenges
  • checkpoint inhibitors
  • refractory solid tumors
  • KRAS G12C-mutant non-small cell lung cancer

Keywords

  • AACR 2026
  • immuno-oncology
  • targeted therapy
  • checkpoint inhibitors
  • PLN-101095
  • denikitug
  • elisrasib
  • KRAS G12C
  • non-small cell lung cancer

Mentioned in this episode

Organizations: Beth Israel Deaconess Medical Center, Yonsei University, MD Anderson Cancer Center

Products: PLN-101095, denikitug, elisrasib

Places: Boston, MA, Seoul, South Korea, Houston, TX

More episodes of VJOncology Podcast

Explore listener stats, chart rankings, contacts and more on the VJOncology Podcast podcast page.